SS-31 (Elamipretide) · Research brief
Elamipretide SS-31 FDA Approval Status 2026
Short answer
As of 2026, the elamipretide SS-31 FDA approval status 2026 question has a two part answer: one finished pharmaceutical product containing elamipretide, marketed as Forzinity, holds an FDA accelerated approval for Barth syndrome, a rare genetic disorder of cardiolipin metabolism, while elamipretide in bulk peptide form, the material catalogued across research suppliers as SS-31, remains an unapproved research chemical that…
As of 2026, the elamipretide SS-31 FDA approval status 2026 question has a two part answer: one finished pharmaceutical product containing elamipretide, marketed as Forzinity, holds an FDA accelerated approval for Barth syndrome, a rare genetic disorder of cardiolipin metabolism, while elamipretide in bulk peptide form, the material catalogued across research suppliers as SS-31, remains an unapproved research chemical that no regulator has cleared for human use. The two share a molecule and nothing else. One is a reviewed, labeled, commercially manufactured product with a defined indication, a confirmatory evidence obligation and a controlled distribution chain. The other is a laboratory reagent supplied for in vitro and preclinical work, with identity and quality documented by certificate of analysis rather than by any regulatory approval. Everything Real Peptides supplies sits in the second category. This page sets out what the public regulatory record shows, what the published trials in primary mitochondrial myopathy and Barth syndrome reported, what the ophthalmology and cardiovascular programs produced, and where the evidence base is thin enough that honest reporting means saying the literature does not specify.
What is the elamipretide SS-31 FDA approval status in 2026?
Elamipretide is approved in the United States only as a branded finished product, Forzinity, and only for Barth syndrome, under the accelerated approval pathway; no approval exists for primary mitochondrial myopathy, dry age related macular degeneration, heart failure, renal disease, sarcopenia, or any longevity or performance indication. That distinction is the whole regulatory story. An approval is granted to a specific application, for a specific indication, in a specific population described by the labeling, manufactured in a specific way. It is not granted to a molecule in the abstract, and it does not travel with the molecule into other supply chains.
The practical consequence for a laboratory is straightforward. Bulk SS-31 offered by research suppliers has not been reviewed by any regulator for safety or effectiveness, carries no approved labeling, and is lawful to purchase only as a research reagent. The existence of an approved product containing the same peptide does not make research grade material a medicine, does not make it equivalent to the approved product, and does not create any route for human use outside a regulated clinical setting.
The second consequence is interpretive. Because an approval now exists, secondary sources, vendor pages and forum posts increasingly blur the line, describing SS-31 as an FDA approved peptide without naming the indication or the pathway. A researcher reading those claims should treat the approved indication as the ceiling of what the agency has accepted, and should treat everything beyond Barth syndrome as investigational or preclinical. Several of the largest trials in the elamipretide program did not meet their primary endpoints, which is the clearest evidence that the molecule's effects are context dependent rather than general.
What is Forzinity, and how does it relate to SS-31 elamipretide?
Forzinity is the United States brand name for the elamipretide finished product that received FDA accelerated approval in September 2025 for Barth syndrome. It is the commercial form of the same aromatic cationic tetrapeptide that laboratories know by the research code SS-31 and by the earlier development codes used during preclinical and early clinical work. The peptide sequence is identical; the product is not.
What separates the two is everything that regulatory review adds. A finished product carries approved labeling that defines the indication and the population it covers, a manufacturing process reviewed against current good manufacturing practice expectations, stability and container closure data, pharmacovigilance obligations and, under accelerated approval, a post marketing confirmatory requirement. Research grade SS-31 carries none of that. It carries an analytical identity, the documentation that the supplying laboratory publishes for the lot, and nothing more.
The approval followed a long and visibly difficult review. The Barth syndrome application went through more than one review extension and a public advisory committee meeting at which outside experts examined whether the available data supported approval in an ultra rare condition where recruiting a conventional confirmatory trial is extremely hard. The agency ultimately used the accelerated pathway, which is reserved for serious conditions with unmet need and rests on an endpoint considered reasonably likely to predict clinical benefit rather than on a demonstrated clinical outcome.
For researchers searching the phrase SS-31 elamipretide Forzinity, the useful takeaway is this: Forzinity names a regulated medicine for an ultra rare cardiolipin disorder affecting a small patient population, while SS-31 names the research compound. Catalog material sold under the SS-31 designation, including the listing Real Peptides maintains at /products/ss-31-elamipretide/, is research use only and is not the approved product.
What does accelerated approval mean in the FDA framework?
Accelerated approval is a regulatory pathway that allows FDA to approve a product for a serious condition with unmet medical need based on an effect on a surrogate or intermediate endpoint that is reasonably likely to predict clinical benefit, rather than on a direct demonstration of that benefit. It is a conditional judgment, not a final one, and the regulations attach obligations to it.
The central obligation is confirmatory evidence. A sponsor that receives accelerated approval is expected to complete post approval studies to verify and describe the clinical benefit that the surrogate predicted. Reforms enacted in recent years tightened the agency's tools here, including authority to require that confirmatory work be underway at the time of approval and to use a more streamlined procedure to withdraw an approval if the confirmatory evidence does not materialise or fails. Accelerated approval therefore means the agency has accepted a probabilistic case, and the full case remains to be made.
The pathway matters for interpreting the elamipretide record because it signals exactly what the agency did and did not conclude. It did not conclude that the peptide produces a proven clinical benefit across mitochondrial disease generally. It concluded that in one ultra rare genetic condition, the available evidence on a predictive endpoint, in the context of serious unmet need and an extremely small eligible population, met the standard for conditional marketing.
For a research audience this is a useful calibration. Accelerated approvals are retrospectively mixed: some are confirmed and converted to traditional approval, some are withdrawn, and some remain unresolved for years while confirmatory trials recruit. Treating an accelerated approval as proof of general efficacy overstates it. Treating it as meaningless understates it. The accurate reading is that a regulator found the evidence sufficient to permit marketing under conditions, in one narrow indication, with the question still open.
Which indications has elamipretide been studied in?
Elamipretide has been studied across a cluster of conditions linked by mitochondrial dysfunction: primary mitochondrial myopathy, Barth syndrome, dry age related macular degeneration including geographic atrophy, heart failure, acute ischaemia reperfusion injury after myocardial infarction, and renal disease, with additional preclinical work in skeletal muscle aging, cardiac aging, ischaemic kidney injury and neurodegeneration models.
The common thread is the molecular target rather than the organ. Cardiolipin, the signature phospholipid of the inner mitochondrial membrane, is required for the structural organisation of cristae and for the assembly and stability of respiratory chain supercomplexes. Where cardiolipin content or remodelling is disturbed, by a genetic lesion as in Barth syndrome, by ischaemia, or by the cumulative changes of aging, bioenergetic output falls and reactive oxygen species production rises. A compound that binds cardiolipin and stabilises that membrane environment is therefore a plausible candidate across many tissues at once, which is precisely why the clinical program fanned out so widely.
Breadth of hypothesis is not breadth of evidence. The strongest regulatory outcome came in the smallest and most genetically defined population, where the defect is directly a cardiolipin remodelling defect. The programs in heterogeneous populations, where mitochondrial dysfunction is one contributor among many, produced far less clear results. That pattern is informative for anyone designing preclinical work: the peptide's measurable effects appear most reliably where the underlying lesion is proximate to its binding partner.
Researchers tracking the field should also note the indications where elamipretide has not been meaningfully studied in controlled human trials despite heavy discussion online, including general healthy aging, cognitive enhancement, exercise capacity in healthy adults and cosmetic applications. For those uses, the published clinical literature does not provide evidence, and the regulatory record contains nothing at all.
What is the SS-31 elamipretide clinical trial status across the program?
The SS-31 elamipretide clinical trial status in 2026 is best described as one narrow indication carried through to conditional approval, several late stage programs that did not meet their primary endpoints, and ophthalmology work that the sponsor has continued to pursue; the live registry entries on ClinicalTrials.gov are the authoritative source for what is currently recruiting.
The program history breaks into phases. Early clinical pharmacology work established tolerability and exposure. A set of mid stage studies in primary mitochondrial myopathy, conducted under the MMPOWER naming convention, examined functional capacity measures such as walking distance and patient reported fatigue. A Phase 3 study in the same indication followed. In parallel, a Phase 2/3 crossover study with an open label extension examined Barth syndrome, and a separate line of work examined ophthalmic indications under the ReCLAIM naming convention. Cardiovascular studies examined reperfusion injury and heart failure, and renal studies examined ischaemic and chronic kidney injury.
For current status, registry records are the correct reference rather than secondary summaries. Entries carry recruitment status, phase, enrolment targets, endpoint definitions and posted results where available, and they are updated by the sponsor under federal reporting requirements. Published peer reviewed reports lag registry postings, sometimes by years, and press releases often describe outcomes in language that the eventual publication qualifies.
One caution applies to every status claim on this topic, including the ones on this page. Trial status changes. A page dated 2026 describes the record as of its writing. Anyone making a procurement or study design decision on the strength of a program's progress should check the registry directly, read the posted results module rather than the summary, and treat any undated vendor claim about ongoing trials as unverified.
What did the primary mitochondrial myopathy trials report?
The Phase 3 trial in primary mitochondrial myopathy did not meet its primary endpoints, and that result is reported in the peer reviewed literature. The MMPOWER-3 randomized clinical trial, published in Neurology in 2023, evaluated elamipretide against placebo in adults with genetically confirmed primary mitochondrial myopathy, using walking distance on a timed walk test and a patient reported fatigue measure as the co primary outcomes. The trial as reported did not demonstrate a statistically significant advantage for the active arm on those endpoints.
That outcome deserves to be read carefully rather than dismissively. Primary mitochondrial myopathy is genetically heterogeneous: the enrolled population carried a wide range of nuclear and mitochondrial DNA lesions with differing tissue distributions and differing degrees of heteroplasmy. A compound acting on membrane organisation may produce measurable bioenergetic change in some of those genotypes and none in others, and a trial powered on the whole group can miss a real effect confined to a subgroup. Equally, the negative result is consistent with the simpler explanation that improving cristae organisation does not translate into measurable walking capacity in a population whose limitation is multifactorial.
Functional endpoints add their own noise. Walking distance over a fixed interval is sensitive to motivation, practice effects, deconditioning and day to day variability, and fatigue scales are sensitive to expectation. These are accepted endpoints in the field because better ones are scarce, not because they are precise.
For laboratory researchers, the useful conclusion is that mitochondrial readouts and whole organism performance readouts are not the same thing, and the gap between them is where this program's difficulties concentrated. Preclinical designs that measure respiratory capacity, supercomplex assembly or reactive oxygen species output should be explicit that those measures are upstream of function, and should not be described as predicting clinical outcome.
What did the Barth syndrome trials report?
The Barth syndrome work combined a randomized crossover phase with a long open label extension, and the published report describes a trial whose blinded portion did not establish a significant difference on its primary measures while the extension phase reported changes over longer follow up. The phase 2/3 randomized clinical trial with open label extension in Barth syndrome, published in Genetics in Medicine in 2021, is the peer reviewed anchor for this part of the program.
Barth syndrome is the cleanest mechanistic case in the entire elamipretide literature. The condition arises from variants in the tafazzin gene, which encodes the acyltransferase responsible for remodelling immature cardiolipin into its mature form. The resulting abnormal cardiolipin profile destabilises the inner mitochondrial membrane and produces cardiomyopathy, skeletal muscle weakness, neutropenia and growth delay. A compound whose defined action is binding and stabilising cardiolipin is therefore aimed directly at the lesion rather than at a downstream consequence.
The trial design reflects the realities of ultra rare disease research. Enrolment was very small, crossover was used to extract more information from few participants, and the open label extension ran for an extended period because a conventional parallel group confirmatory trial is close to impossible at this population size. Each of those choices costs inferential strength. Open label extensions have no placebo control, so improvement over time cannot be cleanly separated from natural history, learning effects or supportive care changes, and the published report is appropriately cautious about this.
This is the body of evidence, together with biomarker and functional data compiled across the program, that the conditional approval ultimately rested on. It explains both why the agency used the accelerated pathway and why a confirmatory obligation attaches: the mechanistic rationale is strong and specific, and the controlled clinical evidence is thin by the standards of larger indications.
Where does the ophthalmology program stand?
The ophthalmology work examined elamipretide in dry age related macular degeneration, including geographic atrophy, under the ReCLAIM naming convention, and the publicly reported outcomes have been mixed rather than definitive. Peer reviewed reporting of this part of the program is more limited than for the myopathy and Barth syndrome studies, so this page describes it qualitatively and does not attach figures to it.
The rationale is tissue specific and reasonable. The retinal pigment epithelium is among the most metabolically demanding tissues in the body, with high mitochondrial density, continuous phagocytic load from photoreceptor outer segments and lifelong oxidative stress exposure. Mitochondrial deterioration in the retinal pigment epithelium is a recognised feature of aging retina and a candidate driver in the progression of dry age related macular degeneration, where no broadly effective intervention has existed. A cardiolipin binding peptide that preserves inner membrane organisation is a coherent candidate in that setting.
Endpoint selection is the hard part. Geographic atrophy trials typically track lesion area growth on imaging, while functional vision endpoints such as low luminance visual acuity capture something patients notice but vary more between visits. A trial can move one and not the other, and the interpretation then depends entirely on which endpoint was specified in advance.
Public reporting across this program has described signals on some measures alongside failure to meet a designated primary endpoint, and the sponsor has described continued late stage ophthalmology work. The exact current recruitment status, endpoint definitions and enrolment targets are registry facts that change, and a researcher who needs them should read them from the registry entry rather than from a summary page. The literature does not currently provide a definitive peer reviewed verdict on elamipretide in retinal disease.
What happened in the cardiovascular and renal studies?
The cardiovascular and renal studies are the oldest part of the clinical program and the part that produced the least regulatory traction. Work in this area examined whether the peptide could limit ischaemia reperfusion injury after myocardial infarction, whether it could improve function in heart failure, and whether it could protect renal tissue in ischaemic and chronic injury settings. None of these lines produced an approval, and the publicly reported primary outcomes did not establish benefit.
The preclinical case was strong, which is part of why the outcome is instructive. Reperfusion injury is a textbook mitochondrial event: restoration of oxygen to ischaemic tissue triggers a burst of reactive oxygen species, calcium overload and permeability transition pore opening, with cardiolipin peroxidation sitting near the centre of the cascade. Animal models showed that interventions at the inner membrane could reduce infarct size and preserve function, and the translational logic from those models to a human reperfusion trial was direct.
Human reperfusion trials have nonetheless defeated a long series of candidate agents. Timing is unforgiving, since the protective window is narrow and overlaps with the interval in which a patient is being moved to the catheterisation laboratory. Modern reperfusion care already limits infarct size substantially, compressing the margin a new agent can add. Infarct size surrogates measured by enzyme release or imaging are noisy. A negative result under these conditions is weaker evidence against a mechanism than a negative result in a slow, stable, well measured condition.
The renal work followed a similar arc, supported by the preclinical literature on mitochondrial protection in ischaemic kidney injury but not converted into a late stage clinical success. For laboratory purposes, these remain active and legitimate model systems. They are not indications with human evidence behind them.
How does SS-31 act at the inner mitochondrial membrane?
SS-31 is a short aromatic cationic tetrapeptide, with alternating aromatic and basic residues and an amidated C terminus, that crosses cell membranes without a transporter, concentrates many fold in the inner mitochondrial membrane and binds cardiolipin, where it is reported to stabilise cristae architecture and improve the efficiency of electron transport. Unlike earlier mitochondria targeted compounds, its accumulation is not driven primarily by membrane potential, which means it can still reach the membrane in tissue where potential has already collapsed.
The mechanistic literature that defined this behaviour is specific. The mitochondrial targeted compound SS-31 re energizes ischemic mitochondria by interacting with cardiolipin, published in the Journal of the American Society of Nephrology in 2013, reported that the peptide associates with cardiolipin, protects cytochrome c from the peroxidase activity that cardiolipin peroxidation enables, and preserves respiratory function in ischaemic tissue. First in class cardiolipin protective compound as a therapeutic agent to restore mitochondrial bioenergetics, published in the British Journal of Pharmacology in 2014, set out the broader framework in which protecting the cardiolipin environment rather than scavenging free radicals is the proposed mode of action, and Serendipity and the discovery of novel compounds that restore mitochondrial plasticity, in Clinical Pharmacology and Therapeutics in 2014, traces how the compound class was identified and what the authors of that review argued its selectivity implies.
Three features of this mechanism matter for experimental design. First, the proposed action is structural and catalytic rather than stoichiometric free radical scavenging, so antioxidant assays alone are a poor readout. Second, the effect depends on cardiolipin being present and accessible, so model systems with intact mitochondria behave differently from isolated enzyme preparations. Third, reported effects concentrate in tissue under bioenergetic stress, meaning healthy control tissue may show little measurable change, which is a design consideration rather than an absence of activity.
What does preclinical research report about SS-31 in aged tissue?
Preclinical work in aged animals reports improvements in mitochondrial energetics and in muscle performance measures, which is the origin of most of the longevity interest in this peptide. Mitochondrial targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice, published in Aging Cell in 2013, is the most cited entry point: it reported that exposure in aged mice was followed by measurable changes in mitochondrial energetic parameters and in skeletal muscle performance over a short interval, a finding that was notable because the change appeared faster than remodelling of mitochondrial content could explain.
The broader preclinical literature describes related observations in cardiac aging, ischaemic injury models and models of oxidative stress, generally reporting preserved respiratory capacity, reduced reactive oxygen species output and better maintained membrane organisation. Studies report these effects most consistently where baseline mitochondrial function is already compromised.
The limits are the familiar ones, and they are substantial. Rodent aging is not human aging; mouse mitochondria differ in reactive oxygen species handling and in lifespan scaling. Short term functional measures in mice do not forecast long term outcomes in people. Exposure conditions in animal work are chosen for the experiment, not matched to anything in human physiology. Most of these studies are small, and publication bias in the aging field is well documented.
The sharpest caution comes from the program's own history. Encouraging preclinical energetics did not convert into a positive Phase 3 functional outcome in human mitochondrial myopathy. That gap is the single most important fact for anyone citing animal aging data in support of broad claims, and it is a reason to describe this literature as mechanistically interesting and clinically unproven. Real Peptides supplies SS-31 for exactly that kind of mechanistic work, and makes no claim beyond it.
Does one branded approval change the status of research-grade SS-31?
No. The approval of a finished product containing elamipretide does not change the legal or practical status of bulk SS-31 supplied as a research reagent, which remains an unapproved substance for research use only. Approval attaches to an application, a manufacturer, a process and an indication, not to a chemical structure in general circulation.
Several consequences follow. Research grade material is not interchangeable with the approved product and cannot be described as equivalent to it. A certificate of analysis establishes the identity and analytical profile of a lot; it does not establish anything about suitability for human use, and no supplier document can. Claims that a peptide is now FDA approved, used as a marketing statement attached to bulk material, misstate the regulatory position even when an approved product containing the molecule exists.
There is also a scientific point hidden in the legal one. The approved indication is an ultra rare genetic cardiolipin remodelling disorder. The mechanistic fit in that condition is unusually direct. Nothing in that approval speaks to effects in healthy tissue, in common age related disease, or in the performance and longevity contexts where the peptide is most discussed outside the literature. A researcher extrapolating from the approval to those settings is extrapolating well past the evidence.
Real Peptides supplies SS-31 as a catalog research compound, listed at /products/ss-31-elamipretide/, with background material collected at /ss-31/. The compound is sold for laboratory research, it is not a medicine, and the company publishes independent third party certificates of analysis for every batch at /coas/ so that identity can be verified before a lot enters an experiment.
How does United States law classify research-use-only peptides?
United States law classifies a peptide like elamipretide by what is claimed for it and how it is distributed, not by the molecule itself. Under the Federal Food, Drug, and Cosmetic Act, an article intended to diagnose, cure, mitigate, treat or prevent disease, or to affect the structure or function of the body, is a drug, and a new drug may not enter interstate commerce for those purposes without an approved application. A substance supplied and labeled strictly as a laboratory research chemical, with no therapeutic claim, is outside that marketing authorisation framework but also outside any clearance for human use.
Clinical investigation of an unapproved drug in people requires an investigational new drug application under the agency's regulations at 21 CFR part 312, together with institutional review board oversight and informed consent. That framework, not a vendor's documentation, is the lawful route by which an unapproved peptide reaches human subjects.
Compounding sits in a separate part of the statute. Sections 503A and 503B set conditions under which pharmacies and outsourcing facilities may compound, including requirements tied to bulk substance eligibility lists maintained by the agency. A substance's presence or absence on those lists is a question of record, and it is distinct from approval status.
Controller substance scheduling is a different framework again, run by the DEA, and peptide therapeutics of this class are generally not scheduled; researchers should verify current status rather than assume it. Anti doping rules form yet another separate system, set by sport organisations rather than by government agencies, with their own prohibited lists that change annually.
This page is general information, not legal advice; consult a qualified attorney for advice on any specific situation.
What documentation should a laboratory check before procuring SS-31?
A laboratory should verify molecular identity, lot specific analytical documentation and the supplier's research use only terms before a compound enters a study. For a peptide like SS-31, identity verification means confirming the sequence and the CAS registry number against the certificate of analysis for the specific lot, not against a general catalog description, because peptide catalogs frequently carry closely related analogues and salt forms under similar names.
The certificate of analysis is the central document. It should be lot specific, it should come from an independent third party laboratory rather than from the seller's own internal assertion, and it should report the analytical methods used, typically mass spectrometry for identity and chromatographic analysis for the purity profile. A certificate that is undated, unsigned, not tied to a lot number, or recycled across multiple lots does not do the job a certificate exists to do.
Supplier terms matter as much as chemistry. Research use only language should be explicit, and a legitimate research supplier does not provide preparation or use guidance, does not make therapeutic claims and does not describe outcomes in people. Real Peptides publishes independent third party certificates of analysis for every batch at /coas/, lists its catalog at /shop/ and publishes its operating location information at /location/, which is the kind of basic verifiable detail a procurement record should capture.
Finally, documentation should be filed with the experiment, not just with the purchase order. Reviewers and collaborators asking how a reagent's identity was established will want the lot number, the certificate, the storage conditions on receipt and the date the lot was opened. That record is what makes a result traceable, and it is independent of any regulatory status the molecule may hold elsewhere.
How should a laboratory think about concentration rather than preparation guidance?
Real Peptides does not provide preparation, handling for use, or application guidance for any catalog compound, because these are research use only materials and such guidance would imply a use that is not permitted. What can be discussed is the general concentration framework that laboratories use when planning any peptide experiment, expressed as mass per volume.
The framework is arithmetic. A lyophilised peptide of known mass, brought into a known volume of solvent, yields a stock concentration in milligrams per millilitre. That stock figure is the reference point for every downstream calculation, and it is the number that should appear in a protocol and in a methods section.
Two details are worth building into a protocol. First, salt form affects the calculation: a peptide supplied as an acetate or trifluoroacetate salt contains less peptide by mass than the nominal figure, and the certificate of analysis or the supplier's specification should be consulted for peptide content before stock concentration is calculated. Second, peptides differ in solubility and in stability in solution, and both properties belong in a methods record.
Nothing in this framework is guidance about use in people, and none of it should be read that way. It is the standard measurement discipline that makes an in vitro result reproducible, and it is the only measurement education appropriate to a research use only compound.
What are the limits of the current elamipretide evidence base?
The limits are considerable, and they should be stated plainly: one conditional approval in an ultra rare genetic condition, a failed Phase 3 in the most closely related indication, mixed public reporting in ophthalmology, no success in cardiovascular or renal late stage work, and a preclinical literature in aging that has not been tested in a dedicated human aging trial.
Sample size is the first limit. The Barth syndrome evidence rests on a very small population, with crossover and open label extension designs that extract maximum information from few participants at the cost of inferential strength. That is a defensible choice in an ultra rare disease and a weak foundation for general claims.
Endpoint heterogeneity is the second. Across the program, walking distance, fatigue scales, imaging measures of lesion growth, visual function and biomarker ratios have all been used. These measures are not comparable to one another, and a positive signal on one does not transfer to another.
Population heterogeneity is the third, and it is the likeliest explanation for the gap between the Barth syndrome and primary mitochondrial myopathy outcomes. Where the genetic lesion sits directly on cardiolipin remodelling, the mechanism and the disease are aligned. Where mitochondrial dysfunction is one feature of a diverse set of genotypes, alignment is partial at best.
The fourth limit is the absence of long term human data outside the approved indication. Exposure over months to years in healthy or aging populations has not been characterised in the published literature, and nothing in the record supports claims about longevity, cognition, exercise capacity or recovery in healthy adults. For those questions, the honest statement is that the literature does not specify.
What should researchers watch in the regulatory record after 2026?
The most informative signal after 2026 will be whether confirmatory evidence for the Barth syndrome accelerated approval is generated and what it shows, because that determines whether the conditional approval converts, persists or is withdrawn. Registry postings and label changes are where that will appear first.
Four other markers are worth tracking. The first is the ophthalmology program: a positive late stage result in geographic atrophy would be a much larger event than the Barth syndrome approval, because the population is vastly bigger and because it would test the cardiolipin hypothesis in an acquired rather than a genetic disorder. The second is any regulatory activity outside the United States, since other agencies apply different standards to the same dossier and their public assessment reports frequently contain analysis that is not available elsewhere. The third is peer reviewed publication of trial data that currently exists only in press material; published reporting routinely qualifies claims that summaries state flatly. The fourth is whether independent groups, outside the original program, replicate the mechanistic findings in new model systems.
For laboratories, the practical posture does not change with any of these outcomes. Research grade SS-31 stays research grade. Its value in a laboratory is as a defined cardiolipin interacting probe for mitochondrial membrane biology, and that value is unaffected by whether a branded product succeeds commercially. What changes is the quality of the published literature available for study design, which is a reason to re check the record rather than to re check a supplier page.
Real Peptides supplies SS-31 as a catalog research compound with independent third party certificates of analysis published for every batch, and makes no therapeutic claim for it.
All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.
References
- The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013. PMID: 23813215. pubmed.ncbi.nlm.nih.gov/23813215
- First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014. PMID: 24117165. pubmed.ncbi.nlm.nih.gov/24117165
- Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clinical Pharmacology and Therapeutics. 2014. PMID: 25188726. pubmed.ncbi.nlm.nih.gov/25188726
- Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013. PMID: 23692570. pubmed.ncbi.nlm.nih.gov/23692570
- A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine. 2021. PMID: 33077895. pubmed.ncbi.nlm.nih.gov/33077895
- Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023. PMID: 37268435. pubmed.ncbi.nlm.nih.gov/37268435
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA